Answers are only as useful as the evidence behind them

Scientific intelligence you can verify.

Amass searches papers, clinical trials, drugs, genes, patents, regulatory records and the live web. Every answer stays connected to its sources, so you can inspect the evidence behind it.

Try free Book a demo

Free plan, $0 forever. No card required.

01App Ask a research question and watch it work: every claim cited, and what it read but didn’t cite shown too. 02MCP Amass inside the tools you already use: Claude, ChatGPT, Claude Code and Codex, over MCP. 03API Build on the engine: typed, cited responses you can program against.

TasksWhich Lp(a)-lowering programs are in phase 3?

Which Lp(a)-lowering programs are in phase 3?

Working…Worked through it

Reasoning

I’m searching TrialCore for phase 3 programs that lower lipoprotein(a), then checking the linked literature for outcomes.

Searched TrialCore

lipoprotein(a) lowering cardiovascular outcomes phase 3

Searched TrialCoreSearching…Completed

Searched BioMedCore

pelacarsen OR olpasiran cardiovascular outcomes

Searched BioMedCoreSearching…Completed

Two phase 3 outcomes programs are on the registry. Lp(a)HORIZON 1(pelacarsen, Novartis Pharmaceuticals) completed in July 2026, and OCEAN(a)-Outcomes 2(olpasiran, Amgen) is active and no longer recruiting, with completion estimated for March 2028 2. An early health technology assessment models both against standard of care 3.

Which Lp(a)-lowering programs are in phase 3?Reply, or steer the research…Reply, or steer the research…

AskBuild Searching all 8 Amass *Cores

See the App →

ClaudeChatGPT

Claude Code

CodexAmass connected

Which Lp(a)-lowering programs are in phase 3?

amasssearch_amass_trialcore_recordsCompleted

query: "lipoprotein(a) cardiovascular outcomes"phase: "PHASE3"

NCT04023552Lp(a)HORIZON · COMPLETED · Novartis Pharmaceuticals

NCT05581303OCEAN(a)-Outcomes · ACTIVE_NOT_RECRUITING · Amgen

Two phase 3 programs: Lp(a)HORIZON (NCT04023552) has completed, and OCEAN(a)-Outcomes (NCT05581303) is active and no longer recruiting.

Reply…

See the MCP →

GEThttps://api.amass.tech/api/v1/cores/trialcore/records?query=NCT04023552&limit=1Authorization: Bearer ••••

200 OKapplication/json

{"data": [{"nctId": "NCT04023552","acronym": "Lp(a)HORIZON","phase": "PHASE3","overallStatus": "COMPLETED","sponsorName": "Novartis Pharmaceuticals","enrollment": 8323,"completionDate": "2026-07-16","referencesBiomedCore": [ "AMBC_…", … ],}]}

See the API →

One question, three ways in: the app with its trace and citations, an assistant calling the Amass tool over MCP, and the API returning the record.

A fluent answer is not a checkable one.

Amass returns each answer with its sources. Each claim carries an identifier that opens the record it came from: a DOI, an NCT ID, a ChEMBL ID, a patent number or a regulatory application number.

peer-reviewed papers: 43M+; BioMedCore
scholarly papers: 233M+; ScholarCore*
patent filings: 170M+; PatentCore
one schema: FDA + EMA; RegulatoryCore
drugs & molecules: 22K+; DrugCore
clinical trials: 1.2M+; TrialCore
human genes: 43K+; GeneCore
real-time web sources: Live; WebCore*

* In the app; the API and MCP serve the other six.

01ScatterYour sources sit on separate platforms
02DriftThe same question gets different answers over time
03ConvergeAmass traces each claim to the record it came from
04CiteEvery answer shows its sources, so the team shares one picture

Research holds the answer

Evidence is scattered across teams, tools and documents.

Reasoning drifts across data, teams and time.

Amass resolves it to the record. Every claim cited to source.

One question about a medicine can touch a journal article, a trial registry, a patent and a regulatory label, then the slides and emails a team writes about them. None of them links to the others.

Each answer starts from whichever documents someone found. A slide repeats one reading of a result, an email another, and the readings drift as they are copied forward. None says where its figure came from.

Behind every claim sits a record, held in the *Core for that kind of source. A slide or an email is not a record, so Amass reads it but never cites it.

JournalBioMedCore: 10.1056/NEJMoa2413258
RegistryTrialCore: NCT04822181
PatentPatentCore: US-2025375504-A1
LabelRegulatoryCore: NDA 215256
SlideQ3 review, slide 12: not a source
EmailRe: MASH readout, v7: not a source

Each reference opens its record. What was read but not cited stays on a list of its own, so the team works from one picture it can check.

BioMedCore

TrialCore

PatentCore

RegulatoryCore

ScholarCore

DrugCore

GeneCore

WebCore

Journal

Semaglutide in MASH, phase 3

Sanyal et al. · N Engl J Med · 2025

10.1056/NEJMoa2413258

Interim cohort

Registry

ESSENCE

Novo Nordisk · Phase 3

NCT04822181

Full enrolment

Slide

Q3 review, slide 12

Team deck · shared drive

No identifier

All randomized

Patent

Semaglutide for use in medicine

Novo Nordisk · filed 2025-08-27

US-2025375504-A1

Label

Wegovy (semaglutide)

FDA · prescribing information

NDA 215256

Email

Re: MASH readout, v7

Email thread · shared drive

No identifier

Early cohort

Read, not cited 2

Q3 review, slide 12

Re: MASH readout, v7

Answer

Semaglutide resolved MASH without worsening fibrosis in more patients than placebo1. The result is the week-72 interim analysis of ESSENCE, read before the full trial completes2.

References4

1Semaglutide in MASH, phase 310.1056/NEJMoa2413258
2ESSENCENCT04822181
3Semaglutide for use in medicineUS-2025375504-A1
4Wegovy (semaglutide)NDA 215256

The platform

One evidence base for researchers, agents and apps.

One record, served three ways: as the app writes it, as the API returns it and as an MCP tool call fetches it. The app searches all eight *Cores; the API and the MCP serve six.

Grounded research across every surfaceUse Amass in the app, through agents, or directly via API and MCP.
One engine over eight *Cores*Cores for papers, trials, drugs, genes, patents, and FDA + EMA regulatory records.
Every claim traceable to sourceAnswers, workflows and outputs stay linked to the underlying evidence.

Researchers

Apps & Agents

Developers

8 *Cores

App

MCP

API

Amass *Core architecture

BioMedCore

43M+

ScholarCore

233M+

PatentCore

170M+

RegulatoryCore

7K+

DrugCore

22K+

TrialCore

1.2M+

GeneCore

43K+

WebCore

Live

Provenance & citations

External data providers

PubMedLiteraturePMCLiteratureCrossrefLiteratureUSPTOPatentsEPOPatentsWIPOPatentsSureChEMBLPatentsFDARegulatoryEMARegulatoryClinicalTrials.govTrialsWHO ICTRPTrialsHGNCGenes & moleculesEnsemblGenes & moleculesUniProtGenes & moleculesChEMBLGenes & moleculesWebWeb

Connect your own data

SharePointYour dataOneDriveYour dataGoogle DriveYour dataDatabricksYour dataS3 / BlobYour dataNetwork drivesYour data

See the three surfaces →

MCP

Inside the assistant you already use.

Amass runs inside Claude, ChatGPT, Claude Code and Codex over the Model Context Protocol (MCP). The assistant calls an Amass tool, and the answer comes back with the identifiers.

Set it up →

ClaudeChatGPT

Claude Code

CodexAmass connected

Which Lp(a)-lowering programs are in phase 3?

amasssearch_amass_trialcore_recordsCompleted

query: "lipoprotein(a) cardiovascular outcomes"phase: "PHASE3"

NCT04023552Lp(a)HORIZON · COMPLETED · Novartis Pharmaceuticals

NCT05581303OCEAN(a)-Outcomes · ACTIVE_NOT_RECRUITING · Amgen

Two phase 3 programs: Lp(a)HORIZON (NCT04023552) has completed, and OCEAN(a)-Outcomes (NCT05581303) is active and no longer recruiting.

Reply…

An assistant calling Amass’s TrialCore search tool, and the two trial records it hands back.

API

The same record, as a response.

Build on the engine with one REST API across six cross-linked *Cores. Each response is typed and carries the identifiers of its sources.

GEThttps://api.amass.tech/api/v1/cores/trialcore/records?query=NCT04023552&limit=1Authorization: Bearer ••••

200 OKapplication/json

{"data": [{"nctId": "NCT04023552","acronym": "Lp(a)HORIZON","phase": "PHASE3","overallStatus": "COMPLETED","sponsorName": "Novartis Pharmaceuticals","enrollment": 8323,"completionDate": "2026-07-16","referencesBiomedCore": [ "AMBC_…", … ],}]}

One trial record from the documented TrialCore records path, as the API returns it.

API docs →

Used by people at

Amass gives our investment team one place to validate science, patents, and trials, with citations we can stand behind in committee.

Luis Toledo

Senior Scientist, Novo Holdings SeedLab

Your research, cited to source.

Start free in the app or with an API key. Enterprise deployments add an SLA, single-tenant hosting and onboarding support.

Try free Book a demo

Data: No training on your data
Hosting: EU-hosted, enterprise
Isolation: Tenant-isolated by architecture
Certification: ISO 27001, SOC 2, NIS2: in motion